Neuroscientific Biopharmaceuticals
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 3 July 2026
- Reported shorts
- 3.8K
- Shares on issue
- 389.719M
Neuroscientific Biopharmaceuticals (NSB) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $629.4KM (source: ASX (Markit))vs $166.1KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$4.7Mvs −$1.8M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.014T (source: Derived: trailing 12 months at year end)vs −$0.013 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- +279.0%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of 2026 Annual Report & Appendix 4E, 25 Aug 2026
NeuroScientific Biopharmaceuticals reported revenue of $629,398 for FY2026, up 279% from the prior year, but net loss widened 154% to $4,693,164. No dividend was declared. The company is focused on advancing its StemSmart™ technology platform and expects continued losses as it progresses clinical development.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −811.6%
- Net margin
- −745.7%
- FCF margin
- −441.4%
- ROE
- −29.7%
- ROA
- −29.2%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $2.6M
- Net debt / EBITDA
- n/a
- Current ratio
- 14.3×
- Interest cover
- −1,391.4×
- Cash dividends paid / net profit
- n/a
- Market cap
- $21.8M
- P/E
- n/a
- P/B
- 1.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $629.4KM (source: ASX (Markit)) | $166.1KM (source: ASX (Markit)) | $2.4MM (source: ASX (Markit)) | $5.1MM (source: ASX (Markit)) |
| Operating income | −$5.1M | −$2.0M | −$2.1M | −$6.1M |
| EBITDA | −$3.3M | −$1.8M | $425.5K | −$1.0M |
| EBIT | −$4.7M | −$1.8M | $334.2K | −$1.1M |
| Interest expense | $3.7K | $2.5K | $10.0K | $4.7K |
| Pretax income | −$4.7M | −$1.8M | $324.2K | −$1.1M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$4.7M | −$1.8M | $324.2K | −$1.1M |
| Net interest income | $223.1K | $163.6K | $168.9K | $102.8K |
| EPS basic | −$0.014T (source: Derived: trailing 12 months at year end) | −$0.013 | $0.002 | −$0.007 |
| EPS diluted | −$0.014T (source: Derived: trailing 12 months at year end) | −$0.013 | $0.002 | −$0.007 |
| Shares | 389.7M | 332.6M | 144.6M | 143.5M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- 2026 Annual Report & Appendix 4EAnnual Results25 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results25 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Oct 2025via asx_announcements
- 2025 Annual Report & Appendix 4EAnnual Results28 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report24 Apr 2025via asx_announcements
- Half Yearly Report and AccountsHalf Year Results26 Feb 2025via asx_announcements
Showing 10 of 22 reports